Clinical Trial Update: Epco, Zanu, Ritux for R/R FL or MZL [Phase 2]

View source ↗

Summary

Phase 2 clinical trial recruiting to evaluate Epco, Zanu, and rituximab in relapsed/refractory follicular lymphoma and marginal zone lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma
• Marginal Zone Lymphoma

Drugs mentioned

• Epco
• Rituximab (rituximab)
• Zanu

Snippet

Sponsor: Reid Merryman, MD | Conditions: Follicular Lymphoma, Lymphoma | Phase 2 | Status: RECRUITING